Ox-01 (Uric Acid)
Acute Ischemic Stroke (adjunct to Mechanical Thrombectomy)
Phase 3Active
Key Facts
Indication
Acute Ischemic Stroke (adjunct to Mechanical Thrombectomy)
Phase
Phase 3
Status
Active
Company
About Freeox Biotech
FreeOx Biotech is a Spanish, private, late-stage clinical company developing Ox-01, a novel adjunct therapy for Acute Ischemic Stroke (AIS). The drug, which is pharmaceutical-grade Uric Acid, aims to improve patient outcomes when administered alongside the current standard-of-care, Mechanical Thrombectomy. Its promising efficacy was uniquely highlighted in a rigorous NIH/NINDS preclinical network study (SPAN), positioning it as a leading candidate to address a major unmet need in stroke care. The company is now preparing for a pivotal Phase III trial to confirm these benefits in humans.
View full company profile